Close Menu
Home › Thermo Fisher Scientific Oncomine Dx Target Test Gets Expanded Regulatory Approval in Japan

Thermo Fisher Scientific Oncomine Dx Target Test Gets Expanded Regulatory Approval in Japan

Feb 26, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Thermo Fisher Scientific said today that Japan's Ministry of Health, Labor, and Welfare has granted expanded approval to its Oncomine Dx Target Test CDx System.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Jan
28
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

What's Popular?

In Molecular Diagnostics

  1. JP Morgan Healthcare, Day 3: Puma Biotechnology, Natera

  2. NTRK Fusion Drug Not Cost Effective for Tumor-Agnostic Use, UK's NICE Suggest

  3. Qiagen, Amgen Collaborate to Develop CDx for Investigational NSCLC Drug

  4. JP Morgan Healthcare, Day 1: Agios Pharmaceuticals, Clovis Oncology, Mirati Therapeutics, and More

  5. Guardant Health to Develop Liquid Biopsy CDx for Amgen KRAS G12C Inhibitor

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.